What is Altimmune?
Altimmune operates at the intersection of advanced pharmacology and metabolic health, focusing on the development of innovative therapies for obesity and liver-related conditions. The company's core value proposition lies in its proprietary research into pemvidutide, a therapeutic agent designed to modulate key biological pathways. By addressing significant unmet medical needs, Altimmune has established itself as a critical player in the biotechnology space, utilizing rigorous clinical trials to validate its novel therapeutic modalities. The firm's strategic focus remains on transforming patient outcomes through precision medicine and scientific excellence, maintaining a robust presence in the competitive landscape of clinical-stage drug development.
How much funding has Altimmune raised?
Altimmune has raised a total of $296.1M across 6 funding rounds:
Multiple Rounds
$66M
Debt
$350K
Grant
$4.7M
Unspecified
$225M
Private Equity (2015): $8M with participation from HealthCap Partners, Bonaventure Capital, Novartis Venture Fund, and Truffle Capital
Share Placement (2015): $16M led by Bonaventure Capital, Novartis Venture Fund, Truffle Capital, and HealthCap Partners
Private Equity (2015): $42M, investors not publicly disclosed
Debt (2020): $350K featuring PPP
Grant (2020): $4.7M backed by U.S. Army Medical Research & Development Command
Unspecified (2026): $225M, investors not publicly disclosed
Key Investors in Altimmune
Bonaventure Capital
A strategic investment firm that partners with visionary founders to provide capital and operational support for impactful businesses.
Novartis Venture Fund
The venture arm of a global pharmaceutical manufacturer specializing in the research and development of innovative medications across multiple therapeutic areas.
Truffle Capital
An independent European business builder focused on financing radical innovation and pioneering technologies within the BioMedTech and Fintech sectors.
What's next for Altimmune?
With the recent influx of capital, Altimmune is poised to transition into a more aggressive phase of clinical execution. The strategic roadmap likely involves scaling the development of pemvidutide, optimizing trial protocols, and potentially expanding its research footprint to address broader metabolic health challenges. As the company moves forward, the focus will shift toward achieving key clinical milestones that could serve as catalysts for future commercialization or strategic partnerships. Investors and stakeholders will be closely monitoring the firm's ability to translate this financial momentum into tangible therapeutic breakthroughs, ensuring that the company remains at the forefront of innovation in the biotechnology industry.
See full Altimmune company page
